Literature DB >> 29962119

Steroid Treatment of Optic Neuropathies.

Leanne Stunkel1, Gregory P Van Stavern2.   

Abstract

The etiologies of optic neuropathy include inflammation, ischemia, toxic and metabolic injury, genetic disease, and trauma. There is little controversy over the practice of using steroids in the treatment of optic neuritis--it is well established that intravenous steroid treatment can speed visual recovery but does not alter final visual function. However, there is controversy surrounding the acceptable routes of administration, dosage, and course of treatment. Additionally, the typical patient with optic neuritis is young and otherwise healthy, and thus is likely to tolerate steroids well. In ischemic and traumatic causes of optic neuropathies, the initial injury is not inflammatory, but damage may be compounded by secondary injury due to resultant inflammation and swelling in the confined space of the optic canal. Steroids have been considered as a means of minimizing inflammation and swelling, and thus minimizing the secondary injury that results. However, the use of steroids in traumatic and ischemic optic neuropathies is highly controversial-the evidence for the efficacy of treatment with steroids is insufficient to show that there is significant benefit. Additionally, patients with these conditions are more likely to have comorbidities that make them vulnerable to significant adverse events with the use of steroids. In this article, we attempt to analyze the current state of the literature regarding the use of steroids in the treatment of optic neuropathies, specifically optic neuritis, nonarteritic anterior ischemic optic neuropathy, and traumatic optic neuropathy. Copyright 2018 Asia-Pacific Academy of Ophthalmology.

Entities:  

Keywords:  optic neuropathies; steroids

Mesh:

Substances:

Year:  2018        PMID: 29962119     DOI: 10.22608/APO.2018127

Source DB:  PubMed          Journal:  Asia Pac J Ophthalmol (Phila)        ISSN: 2162-0989


  4 in total

1.  The development of optic neuropathy after chronic rhinosinusitis: A population-based cohort study.

Authors:  Chan-Wei Nien; Chia-Yi Lee; Pei-Hsuan Wu; Hung-Chi Chen; Jessie Chao-Yun Chi; Chi-Chin Sun; Jing-Yang Huang; Hung-Yu Lin; Shun-Fa Yang
Journal:  PLoS One       Date:  2019-08-07       Impact factor: 3.240

2.  Optic Canal Decompression with a Lateral Approach for Optic Nerve Injury Associated with Traumatic Optic Canal Fracture.

Authors:  Yu Hokazono; Hiroki Umezawa; Yuta Kurokawa; Rei Ogawa
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-10-30

3.  Traumatic Optic Neuropathy Management: A Survey Assessment of Current Practice Patterns.

Authors:  Colin Bacorn; Megan V Morisada; Raj D Dedhia; Toby O Steele; Edward Bradley Strong; Lily Koo Lin
Journal:  J Emerg Trauma Shock       Date:  2021-04-27

4.  An adherent drug depot for retinal ganglion cell protection and regeneration in rat traumatic optic neuropathy models.

Authors:  Lingli Li; Fen Deng; Haijun Qiu; Yao Li; Zan Gong; Lei Wang; Jingjie Wang; Wencan Wu; Kaihui Nan
Journal:  RSC Adv       Date:  2021-06-28       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.